Lataa...
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells
Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3 months. Moreover, sorafenib has severe side effects and patients develop resistance quickly. Epigenetic alterations such as DNA methylation play a deci...
Tallennettuna:
| Julkaisussa: | Int J Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467784/ https://ncbi.nlm.nih.gov/pubmed/28560380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2017.4019 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|